Skip Navigation

Cardiovascular Research 2007 75(1):89-98; doi:10.1016/j.cardiores.2007.03.021
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Corrigendum (v76,p373)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Blaauw, Y.
Right arrow Articles by Allessie, M.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaauw, Y.
Right arrow Articles by Allessie, M.A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat

Y. Blaauw, U. Schotten, A. van Hunnik, H.R. Neuberger and M.A. Allessie*

Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands

* Corresponding author. Department of Physiology, Maastricht University, PO BOX 616, 6200MD Maastricht, The Netherlands. Tel.: +31433881202; fax: +31433884166. m.allessie{at}fys.unimaas.nl

Objective In electrically remodeled atria the effect of blockers of the delayed rectifier K+ current IKr on repolarization is reduced, whereas the efficacy of ‘early’ class III drugs (IKur/Ito/IKach blockers) is enhanced. We evaluated the electrophysiological and antifibrillatory effects of AVE0118, dofetilide, and ibutilide (alone and in combination) on persistent atrial fibrillation (AF) in the goat.

Methods and results The effects of separate and combined administration of AVE0118, dofetilide, and ibutilide were determined before and after 48 h of AF. AVE0118 alone markedly prolonged the atrial refractory period (400 ms cycle length) (AERP400) before and after 48 h of AF. The prolongation of AERP400 by dofetilide and ibutilide, respectively, was reduced by AF from 22±2 to 7±2 ms (p<0.01) and 25±5 to 5±2 ms (p=0.01). Pre-treatment with AVE0118 restored the prolongation of AERP400 by dofetilide or ibutilide (to 20±3 and 30±6 ms; p<0.01). This effect was atrial specific since the QT-interval was not changed. The antifibrillatory action was evaluated in 10 goats that were in persistent AF for 57±7 days. Dofetilide (20 µg/kg/h) or ibutilide (4 mg/h) alone restored sinus rhythm in only 20% of the animals. AVE0118 (1, 3, and 10 µg/kg/h) terminated AF in 11, 30, and 60%, respectively. Additional infusion of IKr blockers caused an additional number of cardioversions, resulting in a final cardioversion rate of 56, 80, and 100%, respectively. AVE0118 alone prolonged the AF cycle length (AFCL) while the conduction velocity during AF (CVAF) remained unchanged (70±1 vs. 68±2 cm/s; p=0.3). Addition of dofetilide or ibutilide caused a synergistic increase in AFCL and a slight increase in CVAF to 74±1 cm/s (p<0.001). The length of the reentrant trajectories increased from 7.6±0.3 (control) to 11.6±0.5 cm after AVE0118 alone (p<0.001) and 14.8±0.8 cm after addition of dofetilide or ibutilide (p<0.001).

Conclusions In electrically remodeled atria, blockade of IKur/Ito/IKAch restored the class III action of IKr blockers. Persistent AF could be effectively cardioverted by infusion of a combination of AVE0118 and dofetilide or ibutilide. This antifibrillatory action was associated with an almost twofold lengthening of the intra-atrial pathways for reentry.

KEYWORDS antiarrhythmia agents; electrophysiology; atrial fibrillation; K-channel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. M. Maleckar, J. L. Greenstein, W. R. Giles, and N. A. Trayanova
K+ current changes account for the rate dependence of the action potential in the human atrial myocyte
Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1398 - H1410.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Europace, July 1, 2009; 11(7): 860 - 885.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. John Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'
Eur. Heart J., June 17, 2009; (2009) ehp235v1.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
J. C. Geller, K. Egstrup, P. Kulakowski, M. Rosenqvist, M. A. Jansson, A. Berggren, N. Edvardsson, P. Sager, and H. J. Crijns
Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009
J. Clin. Pharmacol., March 1, 2009; 49(3): 312 - 322.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.